- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 10 - Additional Sodium Glucose Cotransporter 2 Inhibitors in the Pipeline
Two sodium glucose cotransporter 2 (SGLT-2) inhibitors (canagliflozin and dapagliflozin) have received approval from the FDA. In this segment, Peter Salgo, MD, highlights 2 additional SGLT-2 inhibitors that are currently in the drug pipeline for the treatment of type 2 diabetes mellitus (T2DM).
Jeffrey D. Dunn, PharmD, MBA; Kari Uusinarkaus, MD, FAAFP, FNLA; Dr Salgo; and Yehuda Handelsman, MD, FACP, FACE, FNLA, discuss the need for additional SGLT-2 inhibitors and consider how the availability of more treatment options will affect the costs of treating and managing T2DM.
Together, the experts conclude that as new agents continue to emerge, it will be important to assess and compare their effectiveness in specific patient populations.
Dr Handelsman adds that treatment recommendations are expected to be updated as healthcare professionals gain new insight about the use of SGLT-2 inhibitors in clinical practice.
Maria Lopes, MD, MS, hopes that as more experience is gained in matching appropriate patients to appropriate therapies, real-world use will establish the clinical value of SGLT-2 inhibitors.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
June 23rd 2025Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Read More
